Related Experiment Video

Updated: Oct 17, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.9K

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade

Tian Tian1, Zhaoming Li2

  • 1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Oncology
|October 11, 2021
PubMed

Insights

Combining T cell immunoglobulin and mucin domain molecule 3 (Tim-3) blockade with PD-1/PD-L1 therapy shows promise for overcoming cancer treatment resistance. This approach aims to improve patient response rates in immunotherapy by targeting adaptive resistance mechanisms.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) therapies have revolutionized cancer treatment but are limited by low response rates and acquired resistance.
  • T cell immunoglobulin and mucin domain molecule 3 (Tim-3) is an immune checkpoint receptor that is upregulated in tumors resistant to PD-1/PD-L1 blockade.
  • Overcoming resistance to PD-1/PD-L1 therapy is crucial for improving patient outcomes in cancer immunotherapy.

Purpose of the Study:

  • To systematically review preclinical and clinical data on the combined blockade of Tim-3 and PD-1/PD-L1 in cancer immunotherapy.
  • To explore the potential of dual Tim-3 and PD-1/PD-L1 blockade in overcoming resistance to current immunotherapies.
  • To discuss the future prospects of this combination strategy for enhancing cancer treatment efficacy.

Main Methods:

  • Systematic review of preclinical studies investigating the efficacy of combined Tim-3 and PD-1/PD-L1 blockade.
  • Analysis of clinical trial data evaluating the safety and efficacy of dual checkpoint blockade in various cancers.
  • Discussion of the immunological mechanisms underlying resistance and the rationale for combination therapy.

Main Results:

  • Preclinical data suggest that combined Tim-3 and PD-1/PD-L1 blockade can enhance anti-tumor immune responses and overcome resistance.
  • Early clinical data indicate potential efficacy and acceptable safety profiles for combination therapies in specific cancer types.
  • Upregulation of Tim-3 is a key mechanism of adaptive resistance to PD-1/PD-L1 therapy, making it a rational target for combination.

Conclusions:

  • Combined blockade of Tim-3 and PD-1/PD-L1 represents a promising strategy to enhance cancer immunotherapy efficacy.
  • Targeting Tim-3 may overcome primary and acquired resistance to PD-1/PD-L1 therapies, thereby improving response rates.
  • Further clinical investigation is warranted to establish the role of dual checkpoint blockade in routine cancer treatment.
Keywords:
PD-1PD-L1Tim-3drug resistanceimmune checkpoint

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

660
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K